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In the Oxford dictionary, ‘Independent’ is 
defined as ‘Free from outside control; not 
subject to another's authority’. Indepen-
dence can be critical to identify important 
issues for patients. The authors of the 
paper ‘Safeguarding the future of indepen-
dent, academic clinical cancer research in 
Europe for the benefit of patients’ are to be 
applauded for their strong plea for indepen-
dent investigator-driven research. In addi-
tion, they use this paper to draw attention 
to the Clinical Academic Cancer Research 
Forum (CAREFOR) platform, raised to 
address funding and regulatory challenges 
faced by academic researchers and foster 
collaborative cancer research by developing 
novel approaches to do clinical trials.1 
Thanks to industry-driven studies, over the 
last decades, numerous effective drugs for 
treatment of patients with cancer have been 
registered.
Mounting costs leading to limited afford-
ability as well as side effects of these drugs has 
increased interest in precise insight in the clin-
ical benefit of these drugs for patients. Since 
2015, two scales have been made available 
by, respectively, European Society of Medical 
Oncology (ESMO) and American Society 
of Clinical Oncology (ASCO), namely, the 
ESMO-Magnitude of Clinical Benefit Scale 
(ESMO-MCBS) and the ASCO Framework to 
grade the clinical benefit of drugs.2 3 Applying 
these scales made it clear that far from all 
studies executed to find relevant indications 
for new drugs had a high yield for the patient. 
According to Del Paggio and colleagues, only 
15% of 277 randomised controlled trials 
evaluating systemic therapy for colorectal, 
breast, non-small cell lung and pancreatic 
cancer published between 2011 and 2015 
met ESMO-MCBS thresholds for meaningful 
clinical benefit.4 These authors propose that 
investigators, funding agencies, regulatory 
agencies and industry should adopt more 
stringent thresholds for meaningful benefit 
in the design of future randomised clinical 
trials. Independent research performed by 
academia might especially allow to focus on 
relevant clinical benefit.
Furthermore, several highly relevant clin-
ical questions will not be addressed by the 
pharmaceutical industry. This applies to 
studies including surgery, radiotherapy, 
systemic treatment regimens with non-pat-
ented drugs and de-escalation studies.
Fortunately, there are already multiple 
beautiful examples of independent academic 
studies that indicated their relevance and 
changed treatment paradigms. Recently, 23 
positive Southwest Oncology Group (SWOG) 
trials sponsored by the National Cancer Insti-
tute (NCI) from 1965 to 2012 were analysed in 
which a total of 12 361 patients were enrolled. 
It was estimated that 3.34 million life-years 
were gained from these trials through 2015. 
The return on investment was US$125 per 
life-year gained. The authors concluded that 
NCI’s investment in its cancer cooperative 
group research programme has provided 
exceptional value and benefit to the Amer-
ican public.5
The European Organisation for Research 
and Treatment of Cancer (EORTC) Brain 
Tumour Group study 26 951 is an example 
of a practice changing independent Euro-
pean academic study. This phase III trial 
demonstrated that adjuvant procarbazine, 
lomustine and vincristine administered after 
radiotherapy for anaplastic oligodendro-
glioma improved survival. This became only 
clear after long-term survival analysis with a 
median follow-up of 140 months.6
Such long-term follow-up is typically not 
reported for industry-sponsored studies. 
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Funding of trials like these by a European fund or by 
several National Funds together is essential. There are in 
addition numerous unsolved clinical questions that could 
be of major interest for insurance companies and govern-
ments. Examples are studies investigating treatment 
de-escalation strategies or reducing maintenance therapy, 
in order to limit toxicity and costs while preserving effi-
cacy. For example, the standard of care of patients with 
recurrent or metastatic head and neck squamous cell 
carcinoma, is six cycles of platinum-based chemotherapy 
with cetuximab followed by maintenance therapy with 
cetuximab until disease progression.7 The additive value 
of cetuximab maintenance treatment is unclear, while 
it leads to side effects and additional costs. In the Neth-
erlands, costs for just the drug alone are €27 690 for an 
average male patient with a length of 1.80 m and 80 kg 
body weight on maintenance therapy for 29.9 weeks, 
which was the median duration of maintenance therapy 
in the landmark study.8 A clinical trial comparing six 
cycles of chemotherapy plus cetuximab, with and without 
cetuximab maintenance would therefore be highly rele-
vant. Such a study could be done relatively easy and 
quickly as an independent academic trial when funded 
for data management aspects. For studies investigating 
equivalence of shorter duration of immune checkpoint 
inhibition for approved indications, cost savings could be 
even more pronounced.
Moreover, investigator-driven studies could pay deserved 
attention to patients often excluded for clinical trials even 
though they could tremendously benefit from a clinical 
trial such as patients with second or third malignancies 
and patients with rare tumours or with brain metastases. 
Happily, there is activity in this field as exemplified by the 
EORTC 1206 study ( ClinicalTrials. gov NCT01969578) 
in which patients with metastatic androgen receptor 
positive salivary gland tumours are randomised between 
hormonal therapy and chemotherapy.
The Systemic Therapy in Advancing or Metastatic 
Prostate cancer: Evaluation of Drug Efficacy (STAM-
PEDE) trial is a very elegant and successful example of an 
ongoing independent academic study in which different 
pharmaceutical companies participate. Several experi-
mental treatment arms are compared with an ongoing 
standard of care arm. Ineffective arms are closed early 
and new treatment arms can be added. The set up and 
basic structure of this innovative multiarm, multistage 
platform is funded by Cancer Research UK, Prostate 
Cancer UK and the Medical Research Council, with 
contributions of participating pharmaceutical compa-
nies. All information is freely accessible on the study 
website http://www. stampedetrial. org which supports 
participating centres and patients. Already more than 
9000 patients have been included and two practice 
changing papers have been published.9 10 An European 
funding structure for independent academic trials, 
preferable connected with a cancer research organ-
isation such as EORTC with expertise in conducting 
multinational studies, could advance innovative trials 
after the example of STAMPEDE at the European level.
Not only a new structure for funding of independent 
clinical cancer research is important, also harmonisa-
tion and simplification of regulations will be important. 
Studies with drugs may become easier in Europe when 
the EU clinical trial directive is implemented.
In addition, we will have to nurture and educate the 
next generation of clinical researchers, for example, 
with workshops such as the Methods in Clinical Cancer 
Research (MCCR) Workshop jointly organised by ECCO, 
EORTC, American Association for Cancer Research 
(AACR) and ESMO. Researchers should have basic 
knowledge concerning data infrastructures created for 
assembly of so called ‘big data’, which can reiteratively 
be used multiple times to answer different research 
questions leading in potential to relative cheap scien-
tific breakthroughs. It is clear that also patients need 
insight in this approach as they will be critical partners 
in bringing new approaches forward.
In the past, in trials only structured clinical data was 
collected enabling the researchers to assess efficacy of 
a therapeutic intervention or procedure. Nowadays, 
however, increasingly additional data such as biospec-
imen or omics data, and even patient’s personal metrics 
data assembled with wearable technology, are collected 
to identify, for instance, potential predictive biomarkers 
for the therapy under investigation. This approach is 
rapidly expanding, and interest is also focusing on, for 
example, the ability of omics to predict short-term and 
long-term side effects. However, this data might dramat-
ically increase in power when studies can be combined 
and used to answer other relevant questions not directly 
related to the main research question of the study. A 
clear example of an answer not related to the main 
research question is the development of the Response 
Evaluation Criteria in Solid Tumours (RECIST) for 
which the imaging and outcome data of patients were 
merged from industry as well as cooperative group 
trials. These criteria were developed because changes 
in tumour burden are frequently used as surrogates of 
survival/quality of life. In 2000, the RECIST Working 
Group simplified the 1981 World Health Response 
Criteria (WHO) 2 after validation in a large data ware-
house. In 2009, RECIST was refined (RECIST 1.1) using 
an even larger warehouse and recently, based on data 
of 23 259 patients, RECIST criteria for targeted agents 
were presented.11
Happily, there are now several big initiatives on 
sharing data. With respect to reuse and merging of data, 
an important issue is the ownership of data collected in 
clinical trials. Four potential owners can be identified: 
the public, the participating patients, the investigators 
or the study sponsor. In the ideal setting, any anony-
mous data obtained within clinical trials including 
industry-sponsored trials should be available to other 
interested parties in accordance with the findability, 
accessibility, interoperability, and (re-)usability (FAIR) 
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principle, while observing ethical, legal and societal 
constraints.12 The International Committee of Medical 
Journal Editors (ICMJE) recently proposed that authors 
include a plan for data sharing as part of clinical trial 
registration. Previously, it has been recognised that 
crediting data generators is a key incentive for data 
sharing.13 A proposal has been put forward to acknowl-
edge persons who initially gathered the data with the 
concept called data authorship.14 It states that in order 
to be cited as a data author, a person must have made 
substantial contributions to the original acquisition, 
quality control and curation of the data, be accountable 
for all aspects of the accuracy and integrity of the data 
provided and ensure that the available data set follows 
the FAIR principle. This means that for merging data 
clinical studies we have to get used to very long author 
lists and create solutions as done by the Early Breast 
Cancer Trialists' Collaborative Group.15 Their studies 
already showed that pooling of data from multiple trials 
for so called big-data analyses that can lead to a more 
accurate and complete view of the complexity of the 
data and the problem under investigation. Ultimately, 
this can lead to faster advances in our medical knowl-
edge for the benefit of the patient. Independent clin-
ical researchers should be a major advocate for this data 
sharing approach.
A structure in Europe, in which we united can perform 
Independent, Academic Clinical Cancer Research as 
advocated by Negrouk et al,1 supported by the several 
European states, national charities, insurance compa-
nies, patient organisations and even pharmaceutical 
companies would be of major benefit for the patient 
with cancer and society.
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